Chemical Structure : Ranibizumab
CAS No.: 347396-82-1
货号: PC-Ab1063Not For Human Use, Lab Use Only.
Ranibizumab (Lucentis, RG-6321) is a specific affinity-matured, recombinant, humanized, anti-VEGF antigen-binding antibody fragment (Fab) that binds and neutralizes all the biologically active forms of VEGF-A, an important mediator in the development of choroidal neovascularisation. Ranibizumab was approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD..
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥3580 | In stock | |
5 mg | ¥7580 | In stock | |
10 mg | ¥12800 | In stock | |
100 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Ranibizumab (Lucentis, RG-6321) is a specific affinity-matured, recombinant, humanized, anti-VEGF antigen-binding antibody fragment (Fab) that binds and neutralizes all the biologically active forms of VEGF-A, an important mediator in the development of choroidal neovascularisation. Ranibizumab was approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD.
分子量 | ||
分子式 | Human IgG1-Kappa | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
PBS, pH 7.0 Contains no stabilizers or preservatives |
|
Chemical Name/SMILES |
Ranibizumab; Lucentis; 347396-82-1; RG6321; RG-6321; vascular endothelial growth factor A; VEGFA Fab antibody. |
1. 1, Rosenfeld PJ, et al. N Engl J Med. 2006 Oct 5;355(14):1419-31. 2, Brown DM, et al. N Engl J Med. 2006 Oct 5;355(14):1432-44. 3, Ferrara N, et al. Retina. 2006 Oct;26(8):859-70. 4, Bakri SJ, et al. Am J Ophthalmol. 2007 Mar;143(3):505-7. 5, Gaudreault J, et al. Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright